Different aprotinin applications influencing hemostatic changes in orthotopic liver transplantation.
The effect of different aprotinin applications on hemostatic changes and blood product requirements in orthotopic liver transplantation was investigated in a prospective, open, and randomized study. From November 1989 to June 1990, 13 patients received aprotinin as a bolus of 0.5 Mill. Kallikrein inactivator units (KIU) on three occasions in the course of an OLT, whereas 10 other patients were treated with continuous aprotinin infusion of 0.1-0.4 Mill. KIU/hr. Before and after reperfusion of the graft liver, signs of hyperfibrinolysis, measured by thrombelastography, were significantly lower in the infusion group. Tissue-type plasminogen activator (t-PA) activity increased during the anhepatic phase but to a significantly lesser extent in the infusion group. Blood product requirements during OLT were tendentiously higher in the bolus group but not significantly so. However, the use of packed red blood cells was significantly lower in the postoperative period, whereas there was no significant difference in fresh frozen plasma requirements between the two groups. All 23 patients have survived, and only one woman of each group required retransplantation due to severe host-versus-graft reactions. Furthermore, we investigated the perfusate of the graft liver in both groups and detected signs of a decreased t-PA release in the infusion group. Our results demonstrate an advantage of aprotinin given as continuous infusion over bolus application in OLT.
Himmelreich
G
G
Department of Internal Medicine, University Hospital, Berlin, Germany.
Muser
M
M
Neuhaus
P
P
Bechstein
W O
WO
Slama
K J
KJ
Jochum
M
M
Riess
H
H
D007611:Aprotinin / Q000008:administration & dosage* / Q000494:pharmacology; D004334:Drug Administration Schedule; D005342:Fibrinolysis / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D016031:Liver Transplantation; D011446:Prospective Studies; D011897:Random Allocation; D010959:Tissue Plasminogen Activator / Q000032:analysis
D007611:Aprotinin; D010959:Tissue Plasminogen Activator